Norway's Arctic Bioscience Q1 sales rise 78% to record on  America boost

Arctic Bioscience AS

30/04/2026 06:17

Overview

Norway biotech firm's Q1 sales revenue rose 78% yr/yr to record first-quarter level

Gross margin improved to 34.3% from 27.0% a year earlier

Company secured NOK 15 mln in new long-term financing after quarter-end

Outlook

Company expects strong order outlook to support nutraceutical business growth in 2026

Arctic Bioscience to focus on international expansion of nutraceutical business in 2026

Company to publish HeROPA trial data in H1/H2 2026, aiming to boost visibility and outreach

Result Drivers

ORDER INTAKE - Strong order intake at end of 2025 and into Q1 2026 drove sales growth, per CEO Christer L. Valderhaug

AMERICAN MARKET GROWTH - Continued positive development in the American market contributed the highest revenue share in Q1

IMPROVED GROSS MARGIN - Gross margin rose to 34.3% from 27.0% a year earlier, supported by lower operating expenses

Company press release: ID:nWkr2vlHBG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EBITDA
-NOK 6.50 mln
Q1 Gross Margin
34.30%
Q1 Gross Profit
NOK 4.10 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)